The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Clinical research
Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus
EuroIntervention 2014;10:74-82 published online ahead of print December 2013. DOI: 10.4244/EIJV10I1A13
Si-Hyuck Kang1, MD; Keun Ho Park, MD2; Hyo-Suk Ahn1, MD; Kyung Woo Park1, MD; Young Joon Hong2, MD; Bon-Kwon Koo1, MD; Myung Ho Jeong2, MD; Hyo-Soo Kim*1, MD
1. Cardiovascular Centre, Seoul National University Hospital, Seoul, South Korea; 2. Heart Research Centre of Chonnam National University Hospital, Gwangju, South Korea
Aims: Patients with diabetes mellitus have a higher risk of adverse events after percutaneous coronary intervention (PCI). This study aimed to elucidate the relative efficacy of everolimu